THURSDAY, April 26 (HealthDay News) -- Racial disparities in kidney
transplants for U.S. children have fallen since a new policy was introduced in
2005 by the United Network for Organ Sharing, researchers say.
The policy, called Share 35, preferentially offers kidneys from deceased
donors younger than age 35 to children who need a kidney transplant. While a
kidney from a living donor is preferable, a kidney from a deceased donor can
save a child's life.
Anyhow, it is good news for younger patients with kidney disease. New policy
means younger kidney disease patients may enjoy colorful life by kidney
transplant. While just as the patients told us, it has become more and more
difficult to get a suitable kidney. So kidney transplant isn’t a very good
choice nowadays.
Generally speaking, patients with kidney disease will choose kidney transplant when they have no other better choices. Here I would like to share an
effective treatment with kidney disease patients, which is Immunotherapy in
Shijiazhuang Kidney Disease Hospital.
Immunotherapy are very special, powerful cells found in both humans and
non-human animals. They have been called the centrepieces of regenerative
medicine – medicine that involves growing new cells, tissues and organs to
replace or repair those damaged by injury, disease or aging.
Immunotherapy are the precursors of all cells in the human body. What makes
Immunotherapy cells special is that they are regenerative and malleable. They
have the ability to replicate themselves and to repair and replace other tissues
in the human body. Some tissues, like skin, need constant renewal, which could
not take place without skin Immunotherapys. Other Immunotherapys repair damage
to the body’s tissues, for example, rebuilding damaged or degenerating muscle
tissue. So Immunotherapy therapy can help patients recover the damaged cells in
the kidney.
Is kidney transplant good choice for patients? Kidney transplant or
Immunotherapy therapy? you must have answer.